Delivery Order SPE2DB24D2100-SPE2DB25FBFMW
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,709.46 for Dupixent 300 mg/2 ml pen injections on August 19, 2025. This firm fixed price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply relationship with DLA. The place of performance is listed as Conshohocken, Pennsylvania, the company's corporate headquarters location. This delivery order falls under AmerisourceBergen's comprehensive...
- The Defense Logistics Agency awarded a $6,391.17 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on June 26, 2025, with completion scheduled for June 27, 2025. This firm fixed-price contract, which was competitively awarded with no set-aside designation, represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The company, headquartered in Conshohocken, Pennsylvania, serves as a major...
- The Defense Logistics Agency awarded a $9,133.25 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 ml pen injections. This is a firm fixed price delivery order with an ultimate completion date of July 29, 2025, representing a short-duration pharmaceutical supply contract. The award carries no set-aside designation, indicating it was competitively awarded through open procurement processes. AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a $16,998.05 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 14, 2025, with completion scheduled for July 15, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The delivery is scheduled to occur at AmerisourceBergen's...
- The Defense Logistics Agency awarded a $63,152.32 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 4, 2025, with completion expected by August 5, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $17,474.93 to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 15, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat various allergic and inflammatory conditions, including...
- The Defense Logistics Agency awarded a $34,661.18 delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Dupixent 300 mg/2 ml pens. This competitively awarded, firm fixed-price contract has an ultimate completion date of August 15, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition among qualified vendors. This delivery order operates under...
- The Defense Logistics Agency awarded a $17,619.85 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 23, 2025, with completion scheduled for July 24, 2025. This firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $27,256.30 on August 7, 2025, for the supply of Dupixent 300 mg/2 mL pen injections. The contract represents a firm fixed-price delivery order with an ultimate completion date of August 8, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania facility. This award was competitively awarded with no set-aside designation. This delivery order is issued under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency awarded a $27,728.06 firm fixed-price delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Dupixent 300 mg/2 mL pens (2 mL units). The contract, which is a non-set-aside competitive award with an ultimate completion date of June 3, 2025, represents a delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026....
- SPE2DB24D2100Indefinite Delivery Contract
- SPE2DB24D2100-SPE2DB25FBFMWDelivery Order
The Defense Logistics Agency awarded a $48,351.90 delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Dupixent 300 mg/2 ml pen injections. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 30, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor, AmerisourceBergen supplies critical medical commodities to support military healthcare programs worldwide through its comprehensive IDC vehicle. Dupixent is a biologic medication commonly used in the treatment of atopic dermatitis, asthma, and eosinophilic conditions, and its procurement through DLA supports the Defense Health Agency and other federal healthcare systems. The company's federal contract portfolio demonstrates consistent capability in fulfilling pharmaceutical requirements through open competition, with delivery orders utilizing firm fixed pricing across a broad range of therapeutic categories including specialty medications, brand-name and generic drugs, and medical devices.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $48.4k | 7/29/25 |